Form 4: Tandem Diabetes CFO Reports Planned RSU Vesting & Tax Withholding

Tandem Diabetes Care Inc.'s EVP & CFO, Leigh Vosseller, reported pre-scheduled vesting of restricted stock units and associated tax withholdings under a Rule 10b5-1 plan, resulting in a net increase in direct common stock ownership.

Summary

• Leigh Vosseller, EVP & Chief Financial Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions occurring on November 17, 2025, pursuant to a Rule 10b5-1(c) plan.
• The transactions involved the vesting of two tranches of Restricted Stock Units (RSUs) and their conversion into common stock.
• A total of 1,503 shares of common stock were acquired from the vesting of an RSU award granted on May 25, 2023, at an exercise price of $0.
• Concurrently, 538 shares were disposed of at a price of $18.61 to satisfy tax withholding requirements related to the vesting of the 1,503 RSUs.
• An additional 1,496 shares of common stock were acquired from the vesting of an RSU award granted on May 23, 2024, also at an exercise price of $0.
• Another 536 shares were disposed of at a price of $18.61 to satisfy tax withholding requirements for the vesting of the 1,496 RSUs.
• Following these transactions, Vosseller's direct beneficial ownership of common stock increased to 37,648 shares.
• Vosseller also holds 25,580 shares indirectly through the Leigh A. Vosseller Trust dated January 17, 2010.
• The filing explicitly states that no shares were sold by the reporting person; the dispositions were solely for tax withholding purposes.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled insider transactions related to executive compensation (RSU vesting and tax withholding). It does not contain any new information regarding the company's operational performance, financial health, or strategic direction, thus having a neutral impact on sentiment.

Positives

• The vesting of Restricted Stock Units (RSUs) represents a component of executive compensation, indicating continued alignment of management interests with shareholder value.
• Despite tax withholdings, the reporting person's direct beneficial ownership of common stock increased by a net of 1,925 shares (1,503 + 1,496 538 536), demonstrating a net accumulation of company equity.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating pre-scheduled, non-discretionary transactions, which can reduce concerns about opportunistic insider trading.

Negatives

• A total of 1,074 shares (538 + 536) were withheld by the company to cover tax obligations, reducing the total number of shares received by the executive from the RSU vesting.

Future Outlook

The RSU awards have future vesting schedules, with the May 25, 2023 award vesting 33% on May 15, 2024, and the remainder in eight equal quarterly installments thereafter. The May 23, 2024 award vests 33% on May 15, 2025, with the remainder also in eight equal quarterly installments thereafter, indicating ongoing equity compensation for the executive.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation at Tandem Diabetes Care Inc., a medical device company specializing in insulin delivery systems. Such filings are common across the industry as executives receive and vest equity awards as part of their compensation packages. The use of a Rule 10b5-1 plan for these transactions is a standard practice to manage insider trading compliance.

Comparison to Industry Standards

• The structure of RSU awards and their vesting schedules, as well as the use of tax withholding for equity compensation, are standard practices observed in executive compensation plans across the medical device and broader technology sectors. Companies like Medtronic (MDT) or Dexcom (DXCM) also utilize similar equity incentive plans for their executives.
• The execution of these transactions under a Rule 10b5-1 plan aligns with best practices for corporate governance, providing transparency and mitigating concerns about opportunistic trading by insiders, a common standard among publicly traded companies.

Corporate Governance

Related Party Transactions

• Leigh A. Vosseller holds 25,580 shares indirectly through the Leigh A. Vosseller Trust dated January 17, 2010, of which Leigh Vosseller is the Trustee. This represents a standard related-party disclosure for indirect ownership.

Stakeholder Impact

• Shareholders: The filing indicates a routine compensation event for a key executive, which is generally expected. The net increase in direct ownership by the CFO could be viewed positively as it aligns management's interests with shareholders.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Future quarterly installments of the RSU awards granted on May 25, 2023, will continue to vest.
• Future quarterly installments of the RSU awards granted on May 23, 2024, will continue to vest.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled insider transactions related to executive compensation (RSU vesting and associated tax withholding) under a Rule 10b5-1 plan. It does not provide any new material information regarding Tandem Diabetes Care Inc.'s operational performance, financial outlook, or strategic initiatives that would warrant a change in investment recommendation. The transactions are expected and do not signal any fundamental shift in the company's prospects. Therefore, a 'hold' recommendation is appropriate as there is no new information to alter an existing investment thesis.

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Leigh Vosseller, CFO, Rule 10b5-1 Plan, Tax Withholding, Common Stock